Please login to the form below

lenvatinib

This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
NICE reverses its rejection of Eisai’s Lenvima

The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was able to supply new data on its use. ... that NICE is finally recommending the use of lenvatinib so that patients
NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
NICE backs Eisai's Halaven for breast cancer

The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again
Eisai wins EU licence for kidney cancer drug Kisplyx

The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated assessment. ... We remain committed to exploring the potential of lenvatinib for people with cancer, their

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Medical Director: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Director – Head of Public Affairs: Neg

Senior Account Executive – Medical Communications: Salary TBC

Account Director: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Experienced Editor, London, Medical Communications: Competitive package

Editorial Director – Medical Education: Neg

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Director Healthcare PR Communications: Salary TBC

Scientific Team Lead: Competitive Salary

Account Manager, Healthcare Advertising: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Project / Account Manager (Medical Education): Salary TBC

Account Director - Digital: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...
AstraZeneca: building a new ‘open innovation’ pharma company: The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
In conversation with Pfizer’s Erik Nordkamp: Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...